Sustained release and enhanced oral bioavailability of rivaroxaban by PLGA nanoparticles with no food effect.

Anwer, Md Khalid; Mohammad, Muqtader; Iqbal, Muzaffar; Ansari, Mohd Nazam; Ezzeldin, Essam; Fatima, Farhat; Alshahrani, Saad M; Aldawsari, Mohammed F; Alalaiwe, Ahmed; Alzahrani, Aiman A; Aldayel, Abdullah M

Anwer, Md Khalid; Mohammad, Muqtader; Iqbal, Muzaffar; Ansari, Mohd Nazam; Ezzeldin, Essam; Fatima, Farhat; Alshahrani, Saad M; Aldawsari, Mohammed F; Alalaiwe, Ahmed; Alzahrani, Aiman A; Aldayel, Abdullah M.

Afiliação

Anwer MK; Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia. mkanwer2002@yahoo.co.in.
Mohammad M; Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia.
Iqbal M; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
Ansari MN; Bioavailability Laboratory, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
Ezzeldin E; Department of Pharmacology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia.
Fatima F; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
Alshahrani SM; Bioavailability Laboratory, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
Aldawsari MF; Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia.
Alalaiwe A; Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia.
Alzahrani AA; Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia.
Aldayel AM; Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia.

J Thromb Thrombolysis ; 49(3): 404-412, 2020 Apr.

Article em En | MEDLINE | ID: mdl-31898270

Assuntos

Nanopartículas; Copolímero de Ácido Poliláctico e Ácido Poliglicólico; Rivaroxabana; Administração Oral; Animais; Disponibilidade Biológica; Preparações de Ação Retardada/química; Preparações de Ação Retardada/farmacocinética; Preparações de Ação Retardada/farmacologia; Interações Alimento-Droga; Masculino; Nanopartículas/química; Nanopartículas/uso terapêutico; Copolímero de Ácido Poliláctico e Ácido Poliglicólico/química; Copolímero de Ácido Poliláctico e Ácido Poliglicólico/farmacocinética; Copolímero de Ácido Poliláctico e Ácido Poliglicólico/farmacologia; Ratos; Ratos Wistar; Rivaroxabana/química; Rivaroxabana/farmacocinética; Rivaroxabana/farmacologia

Palavras-chave

Bioavailability; Food effect; Nanoparticles; PLGA; Rivaroxaban

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nanopartículas / Rivaroxabana / Copolímero de Ácido Poliláctico e Ácido Poliglicólico Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google